The reporting methods of noninferiority randomized clinical trials are often inconsistent, with many publications omitting information crucial to clinical decision-making, according to a study.
In a recent study published in the Journal of Investigative Dermatology, Kevin S. Kim, MD, PhD, a first-year dermatology resident at the University of Ottawa, and colleagues explained that the role of noninferiority randomized clinical trials is to establish the best medical intervention for patients based on the treatment’s efficacy compared with an existing FDA-approved therapy. These trials can